摘要
目的探讨不规则抗体检测及IgG抗-A(B)血型抗体效价在多次妊娠史孕妇产前检查中的价值,以实际应用提供参考依据。方法110例产妇,根据产妇孕次分为对照组(初次妊娠产妇)和研究组(多次妊娠产妇),每组55例。两组产妇均予以不规则抗体检测,并对两组O型产妇进行产前IgG抗-A(B)血型抗体效价检测。比较两组产妇不规则抗体阳性率,O型产妇IgG抗-A(B)血型抗体效价阳性率。结果研究组不规则抗体阳性率为10.91%,高于对照组的0,差异具有统计学意义(χ^(2)=6.346,P<0.05)。研究组O型产妇IgG抗-A(B)血型抗体效价阳性率为72.73%,高于对照组的35.00%,差异具有统计学意义(χ^(2)=6.019,P<0.05)。结论为确保优生优育,应加强多次妊娠产妇产前不规则抗体及IgG抗-A(B)血型抗体效价,以早期诊断并干预新生儿溶血病发生,以促进新生儿健康水平提升,保障人口质量。
Objective To discuss the value of irregular antibody detection and IgG anti-A(B)blood group antibody titer in prenatal examination of pregnant women with multiple pregnancy history,so as to provide reference for practical application.Methods A total of 110 cases of pregnant women were divided into control group(first pregnancy)and research group(multiple pregnancy)according to the number of pregnancies,with 55 cases in each group.Both groups were tested for irregular antibody,and the prenatal IgG anti-A(B)blood group antibody titer was tested for pregnant women with blood type O of the two groups.Comparison was made on the positive rate of irregular antibody,and the positive rate of IgG anti-A(B)blood group antibody titer of pregnant women with blood type O between the two groups.Results The positive rate of irregular antibody in the research group was 10.91%,which was higher than 0 in the control group,and the difference was statistically significant(χ^(2)=6.346,P<0.05).In the research group,the positive rate of IgG anti-A(B)blood group antibody titer of pregnant women with blood type O was 72.73%,which was higher than 35.00%in the control group,and the difference was statistically significant(χ^(2)=6.019,P<0.05).Conclusion In order to ensure eugenics,it is necessary to strengthen the titer of prenatal irregular antibody and IgG anti-A(B)blood group antibody in pregnant women with multiple pregnancy,so as to diagnose and intervene the occurrence of neonatal hemolytic disease in early stage,and promote the health level of newborns and ensure the quality of population.
作者
王品
WANG Pin(Department of Clinical Laboratory,Baoshihua Hospital,Panjin 124010,China)
出处
《中国现代药物应用》
2021年第17期76-78,共3页
Chinese Journal of Modern Drug Application
